Description
Belzutifan
Each film-coated tablet contains: Belzutifan … 40mg.
INDICATION
LuciBelzu is a hypoxia-inducible factor inhibitor indicated for treatment of adult patients with von Hippel -Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic ne uroendocrine tumors (pNET), not requiring immediate surgery.
DOSAGE AND USE
The recommended dosage of LuciBelzu is 120 mg administered orally once daily with or without food.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer LuciBelzu during Pregnancy and Lactation.
Reviews
There are no reviews yet.